Hicks S, Frias J, Mishra S, Scotti M, Muscato D, Valero M
Mol Ther Nucleic Acids. 2024; 35(4):102338.
PMID: 39391766
PMC: 11465180.
DOI: 10.1016/j.omtn.2024.102338.
Almeida C, Robriquet F, Vetter T, Huang N, Neinast R, Hernandez-Rosario L
Front Cell Dev Biol. 2023; 11:1181040.
PMID: 37397246
PMC: 10309041.
DOI: 10.3389/fcell.2023.1181040.
Porquet F, Weidong L, Jehasse K, Gazon H, Kondili M, Blacher S
Mol Ther Nucleic Acids. 2023; 32:857-871.
PMID: 37273786
PMC: 10238591.
DOI: 10.1016/j.omtn.2023.05.007.
De Serres-Berard T, Ait Benichou S, Jauvin D, Boutjdir M, Puymirat J, Chahine M
Int J Mol Sci. 2022; 23(21).
PMID: 36362145
PMC: 9657934.
DOI: 10.3390/ijms232113359.
Izzo M, Battistini J, Provenzano C, Martelli F, Cardinali B, Falcone G
Int J Mol Sci. 2022; 23(9).
PMID: 35563013
PMC: 9101876.
DOI: 10.3390/ijms23094622.
Targeting Myotonic Dystrophy Type 1 with Metformin.
Garcia-Puga M, Saenz-Antonanzas A, Matheu A, de Munain A
Int J Mol Sci. 2022; 23(5).
PMID: 35270043
PMC: 8910924.
DOI: 10.3390/ijms23052901.
Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1.
Liu J, Guo Z, Yan X, Yang Y, Huang S
Front Aging Neurosci. 2021; 13:755392.
PMID: 34867280
PMC: 8634727.
DOI: 10.3389/fnagi.2021.755392.
Skeletal Muscle Mitochondria Dysfunction in Genetic Neuromuscular Disorders with Cardiac Phenotype.
Ignatieva E, Smolina N, Kostareva A, Dmitrieva R
Int J Mol Sci. 2021; 22(14).
PMID: 34298968
PMC: 8307986.
DOI: 10.3390/ijms22147349.
Antisense Transcription across Nucleotide Repeat Expansions in Neurodegenerative and Neuromuscular Diseases: Progress and Mysteries.
Castro A, Loureiro J, Bessa J, Silveira I
Genes (Basel). 2020; 11(12).
PMID: 33261024
PMC: 7760973.
DOI: 10.3390/genes11121418.
From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital Myopathies.
Sztretye M, Szabo L, Dobrosi N, Fodor J, Szentesi P, Almassy J
Int J Mol Sci. 2020; 21(23).
PMID: 33255644
PMC: 7728138.
DOI: 10.3390/ijms21238935.
Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S, Hanson B, Wood M, Varela M, Roberts T
Mol Ther. 2020; 28(12):2527-2539.
PMID: 33171139
PMC: 7704741.
DOI: 10.1016/j.ymthe.2020.10.005.
Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement.
La Rosa P, Petrillo S, Bertini E, Piemonte F
Biomolecules. 2020; 10(5).
PMID: 32369911
PMC: 7277112.
DOI: 10.3390/biom10050702.
AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E, Konieczny P, Cywoniuk P, Dluzewska J, Sobczak K
Nucleic Acids Res. 2020; 48(5):2531-2543.
PMID: 31965181
PMC: 7049696.
DOI: 10.1093/nar/gkaa007.
Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1.
Timchenko L
Int J Mol Sci. 2019; 21(1).
PMID: 31877772
PMC: 6982105.
DOI: 10.3390/ijms21010094.
Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1.
Yin Q, Wang H, Li N, Ding Y, Xie Z, Jin L
Cell Res. 2019; 30(2):133-145.
PMID: 31853004
PMC: 7015062.
DOI: 10.1038/s41422-019-0264-2.
RNA toxicity in non-coding repeat expansion disorders.
Swinnen B, Robberecht W, Van Den Bosch L
EMBO J. 2019; 39(1):e101112.
PMID: 31721251
PMC: 6939197.
DOI: 10.15252/embj.2018101112.
Cell-type-specific dysregulation of RNA alternative splicing in short tandem repeat mouse knockin models of myotonic dystrophy.
Nutter C, Bubenik J, Oliveira R, Ivankovic F, Sznajder L, Kidd B
Genes Dev. 2019; 33(23-24):1635-1640.
PMID: 31624084
PMC: 6942047.
DOI: 10.1101/gad.328963.119.
Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic Dystrophy.
Sznajder L, Swanson M
Int J Mol Sci. 2019; 20(13).
PMID: 31323950
PMC: 6651174.
DOI: 10.3390/ijms20133365.
Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1.
Hintze S, Knaier L, Limmer S, Schoser B, Meinke P
Front Physiol. 2018; 9:1532.
PMID: 30425655
PMC: 6218431.
DOI: 10.3389/fphys.2018.01532.
Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.
Wang Y, Hao L, Wang H, Santostefano K, Thapa A, Cleary J
Mol Ther. 2018; 26(11):2617-2630.
PMID: 30274788
PMC: 6225032.
DOI: 10.1016/j.ymthe.2018.09.003.